CME Information
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Global Services, LLC.
Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with XLRP.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize important advances in retinitis pigmentosa GTPase Regulator (RPGR) research that have increased understanding of its function and led to the development of potential therapies, including gene replacement therapy.
- Assess the landscape of investigational gene therapies, their mechanisms of action, efficacy, and safety in patients with XLRP.
Activity Chair
Byron L. Lam, MD
Greene Professor
Bascom Palmer Eye Institute
University of Miami
Miami, FL
Faculty
Lesley Everett, MD, PhD
Assistant Professor of Ophthalmology
Divisions of Ophthalmic Genetics & Retina
Casey Eye Institute
Oregon Health & Science University
Portland, OR
M. Dominik Fischer, MD, PhD, FEBO
Professor of Ophthalmology
University of Tuebingen
Tuebingen, Germany
University of Oxford
Oxford, UK
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, February 1, 2022, to January 31, 2023.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Activity Chair and Faculty report the following relevant financial relationship(s)
Byron L. Lam, MD
Consultant: Biogen, Janssen, ProQR
Independent Research Contractor: AGTC, Biogen, Janssen, ProQR, Spark
Lesley Everett, MD, PhD
No relevant financial relationships to disclose.
M. Dominik Fischer, MD, PhD, FEBO
Consultant: Janssen
Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com